Myasthenie.com

Immunol Lett. 2025 Feb 10:106983. doi: 10.1016/j.imlet.2025.106983. Online ahead of print.

ABSTRACT

OBJECTIVE: Myasthenia gravis (MG) is an autoimmune disease characterized by disrupted neuromuscular synaptic transmission. Efgartigimod, a human Fc receptor antagonist, has been approved for patients with MG. Its potential use for other IgG-mediated neurological autoimmune diseases is unclear. This study aimed to retrospectively evaluate the efficacy and safety of efgartigimod in patients with neurological autoimmune diseases.

METHODS: This retrospective study investigated patients with neurological autoimmune diseases who were treated with efgartigimod in the Henan Provincial People's Hospital. The efficacy of the medication was analyzed using the quality-of-life improvement score and the IgG level pre- and post-efgartigimod treatment. The safety of the medication was assessed by considering adverse events and blood parameters. The blood parameters, including routine blood parameters, coagulation, liver, kidney, and immune function.

RESULTS: Seventeen patients received efgartigimod in the Henan Provincial People's Hospital from September 1, 2023, to January 31, 2024. In MG patients, myasthenia gravis activities of daily living (MG-ADL) reduced after efgartigimod treatment for 4 weeks compared with baseline (P0.05). There were no changes in blood parameters during the treatment (P>0.05).

CONCLUSIONS: Efgartigimod was effective and safe in neurological IgG-mediated autoimmune diseases, even in patients without increased IgG serum levels.

PMID:39938695 | DOI:10.1016/j.imlet.2025.106983


Source: https://pubmed.ncbi.nlm.nih.gov/3993869 ... t9+e462414